Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial.

ABSTRACT:

Background

The long-term cancer safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in real-world settings remains unclear, with limited long-term clinical and observational studies. We clarify the long-term cancer risk.

Methods

This register-based nationwide emulated trial includes all Danes initiating treatment with GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i) 2007-2019, propensity score matched 1:1 on baseline characteristics and followed 10 years. The primary outcome was risk differences for cancer, estimated for long-term sustained use of GLP-1RA vs DPP-4i using g-computation accounting for time-varying patient characteristics. Secondary outcomes included "death without prior cancer" and the composite outcome "death or cancer". Analyses included sex

SUBMITTER: Gamborg M 

PROVIDER: S-EPMC12426824 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature